Clinical Trials

733 enrolled 21 charts 3 FDA

GastrointestinalGynecologic

Ovarian Neoplasms

NCT03367247 2026-03-10

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Phase NA Completed

121 enrolled 16 charts

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04024254 2026-03-04

A Study of Serum Folate Levels in Patients Treated With Olaparib

Phase 4 Completed

10 enrolled 14 charts

BreastGynecologic

Breast Neoplasms, Folic Acid Deficiency, Ovarian Neoplasms

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT03763838 2026-02-05

Acupressure for Fatigue in Ovarian Cancer Survivors

Phase NA Completed

171 enrolled 14 charts

Phase 1/2 Active not recruiting

Fatigue, Ovarian Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05041257 2026-01-09

PICCOLO

79 enrolled 14 charts

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

7 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT02948426 2026-01-08

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Phase 1 Terminated

18 enrolled 19 charts

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Phase 1 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

4 enrolled 8 charts

Phase 1 Active not recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04339140 2025-12-11

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

5 enrolled 4 charts

Ovarian Neoplasms

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 2 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

36 enrolled 11 charts

Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02068794 2025-11-18

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

34 enrolled 12 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

GastrointestinalGynecologicThoracic

166 enrolled 43 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT03519178 2025-11-14

A Study of PF-06873600 in People With Cancer

155 enrolled 44 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03839524 2025-11-14

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Phase 1 Completed

64 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04106492 2025-11-14

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

GynecologicHead & NeckSarcomaThoracic

53 enrolled 23 charts

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma, Uterine Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

GastrointestinalGynecologicThoracic

8 enrolled 12 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies